好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing Early and Late-onset Epilepsy: Insights into Distinct Clinical Entities
Epilepsy/Clinical Neurophysiology (EEG)
P4 - Poster Session 4 (8:00 AM-9:00 AM)
10-006

This retrospective, single-center study investigated the differences in clinical presentation, seizure characteristics, and workup between late-onset-epilepsy(LOE) and early-onset-epilepsy(EOE) to improve prognostication and develop targeted interventions.

LOE is an entity distinct from EOE. It poses unique diagnostic and therapeutic challenges.  Despite this, LOE remains understudied. Further research can elaborate on how it differs to optimize management strategies.

All patients who presented to our hospital with clinically-diagnosed epilepsy from 8/2024-9/2024 were included. Patients were categorized into EOE vs LOE based on an age-at-onset-cutoff of 65 years. Data on baseline demographics, seizure characteristics, comorbidities, and workup were obtained from EMR. Data were analyzed using Pearson’s Chi-squared test, Fisher's exact test, or t-tests.

Of the 74 patients meeting the inclusion criteria, 37(50%) were LOE. The mean age at epilepsy onset was 57.7±8.2 years for EOE and 72.8±6.3 years for LOE(p<0.001). Women were more likely to have LOE than EOE(LOE=62.2% vs EOE=37.8%,p=0.0377).  LOE were more likely to be white than non-white(89.2% vs 70.3%,p=0.0496). EOE were more likely to be disabled than LOE(16.2% vs 0%,p=0.010). The burden of comorbidity was significantly greater in LOE(mean Charlson-Comorbidity-Index:5.11±2.07 vs.3.84±1.95,p=0.0082). Both groups had similar proportions of focal and generalized seizures. Drug-resistant-epilepsy(DRE) was observed in 4(10.8%)EOE, against none in LOE. Routine EEG was performed in 25(67.6%)EOE and 27(73.0%)LOE; seizures were recorded in one patient from each group. Epileptiform discharges or seizures were comparable in EOE and LOE(28.0% vs 25.9%). Overall, 92.5% of patients had MRI abnormalities.

LOE and EOE patients exhibit distinct clinical profiles, with LOE patients more frequently female and white, and demonstrating greater comorbidity and lower levels of disability. DRE was observed only in EOE. EEG findings revealed epileptiform abnormalities in >25% of the overall cohort. These differences underscore the need to investigate LOE as a distinct epilepsy type to develop individualized management strategies based on age of onset.

Authors/Disclosures
Syeda Amrah Hashmi, MBBS
PRESENTER
Dr. Hashmi has nothing to disclose.
Muhammad Asjad Abbas, MBBS Dr. Abbas has nothing to disclose.
Amirmohammad Eghbalnejadmofrad, MD Dr. Eghbalnejadmofrad has nothing to disclose.
Mark S. Quigg, MD (UVA Neurology) Dr. Quigg has received personal compensation for serving as an employee of Natus. Dr. Quigg has received personal compensation for serving as an employee of Neurocrine. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Finnigen and Harrison. Dr. Quigg has received research support from NIH. Dr. Quigg has received publishing royalties from a publication relating to health care.
Jaideep Kapur, MD, PhD (UVA Neurology) The institution of Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Marinus. Dr. Kapur has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Robert Wood Johnson Foundation . Dr. Kapur has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Kapur has received research support from NIH. Dr. Kapur has received intellectual property interests from a discovery or technology relating to health care. Dr. Kapur has a non-compensated relationship as a Chair, Board North America with International League against Epilepsy that is relevant to AAN interests or activities. Dr. Kapur has a non-compensated relationship as a Board of Directors with American Epilepsy Society that is relevant to AAN interests or activities.
Ifrah Zawar, MD (University of virginia) The institution of Dr. Zawar has received research support from Alzheimer's association. The institution of Dr. Zawar has received research support from American epilepsy society . The institution of Dr. Zawar has received research support from NIH. The institution of Dr. Zawar has received research support from University of Virginia.